Tilenka Thynne

Tilenka Thynne

Auto-generated profile, based on publicly available information

Tilenka Thynne

Australian Prescriber

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2021 in Journal of Diabetes
Verified
Journal Article
Open access
PDF file
GRGregory Roberts
Gregory Roberts
JSJames Sires
James Sires
ACAngela Chen
Angela Chen
TTTilenka Thynne
Tilenka Thynne
CSCheyne Sullivan
Cheyne Sullivan
EMEmily Jane Meyer
Emily Jane Meyer
Background: The aim of this study is to compare metrics specific for stress‐induced hyperglycemia (SIH) with glucose for predicting ischemic stroke outcome.Methods: This observational retrospective study (n = 300) included patients acutely hospitalized for ischemic stroke over a 3.8‐year period. We assessed the association between acute ischemic stroke outcome with the stress hyperglycemia ratio (SHR, relative increase in glycemia) and glycemic gap (GG, absolute increase in glycemia) using admission values and 5‐day maximum values, along with incidence of poor outcome above recognized clinical thresholds of glucose 10 mmol/L, SHR 1.14, and GG 2.5 mmol/L.Results: At admission, only SHR was associated with outcome after adjustment for clinical covariates (odds ratio [OR] = 2.88; 95% CI: 1.05‐7.91; P = .041), while glucose or GG were not. Admission SHR ≥ 1.14 was also an indicator of poor outcome (39.1% vs 23.4%, P = .016), but not glucose ≥10 mmol/L or GG ≥ 2.5 mmol/L. All 5‐day maximum glucose metrics were associated with outcome, as was any SHR ≥ 1.14 (40.9% vs 20.1%, P < .001) or GG ≥ 2.5 mmol/L (42.9% vs 23.4%, P = .011), but not glucose ≥10 mmol/L. Increased comorbidity was strongly associated with worse outcome (P < .001) in all models.Conclusions: SHR provided the best prognostic insight at admission to assess the relationship between SIH and ischemic stroke outcome. Absolute glucose levels failed to account for natural interpatient variation in background glycemia and provided little prognostic insight. To assess the impact of SIH, future interventional studies need to be designed using designated markers of SIH such as SHR in preference to absolute glucose.

1 November 2014 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
LGLucia Gagliardi
Lucia Gagliardi
MNMarni A. Nenke
Marni A. Nenke
TTTilenka R. J. Thynne
Tilenka R. J. Thynne
JBJenny von der Borch
Jenny von der Borch
WRWayne A. Rankin
Wayne A. Rankin
DTDavid J. Torpy
David J. Torpy
Patients with Addison's disease (AD) report impaired subjective health status (SHS). Since cortisol exhibits a robust circadian cycle that entrains other biological clocks, impaired SHS may be due to the noncircadian cortisol profile achieved with conventional glucocorticoid replacement. Continuous subcutaneous hydrocortisone infusion (CSHI) reproduces a circadian cortisol profile, but its effects on SHS have not been objectively evaluated. The aim of this study was to determine the effect of CSHI on SHS in AD. This was a multicentre, double-blind, placebo-controlled trial of CSHI vs oral glucocorticoid therapy. Participants received in random order 4 weeks of: CSHI and oral placebo, and subcutaneous placebo and oral hydrocortisone, separated by a 2-week washout period. SHS was assessed using the Short-Form 36 (SF-36), General Health Questionnaire (GHQ-28), Fatigue Scale (FS), Gastrointestinal Symptom Rating Scale (GSRS); and Addison's Quality of Life Questionnaire (AddiQoL). Participants were asked their (blinded) treatment preference. Twenty-four hour urine free cortisol (UFC) and diurnal salivary cortisol collections compared cortisol exposure during each treatment. Ten participants completed the study. Baseline SHS scores (mean ± SE) were consistent with mild impairment: SF-36 physical component summary 48.4 (± 2.4), mental component summary 53.3 (± 3.0); GHQ-28 18.1 (± 3.3); GSRS 3.7 (± 1.6), and AddiQoL 94.7 (± 3.7). FS was similar to other AD cohorts 13.5 (± 1.0) (P = 0.82). UFC between treatments was not different (P = 0.87). The salivary cortisol at 0800 h was higher during CSHI (P = 0.03), but not at any other time points measured. There was no difference between the treatments in the SHS assessments. Five participants preferred CSHI, four oral hydrocortisone, and one was uncertain. Biochemical measurements indicate similar cortisol exposure during each treatment period, although a more circadian pattern was evident during CSHI. CSHI does not improve SHS in AD with good baseline SHS. This casts some doubt on the potential benefit of circadian cortisol delivery on SHS in AD.

21 February 2017 in Drugs & Aging
Verified
Journal Article
Closed access
PDF file
TWTom D. Wilsdon
Tom D. Wilsdon
IHIvanka Hendrix
Ivanka Hendrix
TTTilenka R. J. Thynne
Tilenka R. J. Thynne
Arduino MangoniArduino Mangoni
Arduino Mangoni

18 January 2019 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
TWTom D Wilsdon
Tom D Wilsdon
SWSamuel L Whittle
Samuel L Whittle
TTTilenka Rj Thynne
Tilenka Rj Thynne
Arduino MangoniArduino Mangoni
Arduino Mangoni

25 April 2018 in Therapeutic Advances in Drug Safety
Verified
Journal Article
Open access
PDF file
TPThomas M. Polasek
Thomas M. Polasek
MDMatthew P. Doogue
Matthew P. Doogue
TTTilenka R.J. Thynne
Tilenka R.J. Thynne
With the increasing prevalence of type 2 diabetes mellitus (T2DM) in women of childbearing age, prescribing antidiabetic medications in first-trimester pregnancy is becoming more common. Metformin treatment during this time is usually avoided in countries with well-resourced healthcare. This is based on historical concerns about safety to the foetus and the widespread availability of insulin. However, there is now increasing interest in the potential benefits of metformin in pregnant women with T2DM. In this commentary, the main evidence supporting metformin safety in pregnancy is summarized, with an emphasis on the first trimester. Based on a structured literature search, the recent randomized controlled trials comparing metformin and insulin are reviewed. We then show that prescribing advice for metformin in pregnancy is inconsistent and product information/package inserts (PI) are universally out of date. This causes confusion and pushes some women and their clinicians to change from metformin to insulin. The potential advantages of metformin in pregnant women with T2DM are then discussed, including oral dosing and improved acceptability, lower resource utilization and cost, decreased insulin requirements, less maternal weight gain and less risk of maternal and neonatal hypoglycaemia. The conclusion is that metformin is a cheap and efficacious antidiabetic medication for many pregnant women with T2DM, with reasonable evidence for safety. Drug information resources should be updated so that metformin can be considered more broadly in women with T2DM who present for antenatal care.

22 August 2023 in Australian Prescriber
Verified
Journal Article
Open access
PDF file
TTTilenka Rj Thynne
Tilenka Rj Thynne
GGGenevieve M Gabb
Genevieve M Gabb
Reporting suspected adverse drug reactions is critical to increasing knowledge on drug safety for a broader spectrum of the population than is considered in randomised controlled trials.